Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy

Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy

Abstract The Kirsten rat sarcoma (KRAS) oncoprotein has been on drug hunters list for decades now. Initially considered undruggable, recent advances have successfully broken the jinx through covalent inhibition that exploits the mutated cys12 in the switch II binding pocket (KRASG12C). Though this a...

Full description

Bibliographic Details
Main Authors: Abdul Rashid Issahaku, Namutula Mukelabai, Clement Agoni, Mithun Rudrapal, Sahar M. Aldosari, Sami G. Almalki, Johra Khan
Format: Article
Language:English
Published: Nature Portfolio 2022-10-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-22668-1

Internet

https://doi.org/10.1038/s41598-022-22668-1

Similar Items